Phase I Safety and Biodistribution Study of 124I-PEG-AVP0458 Diabody in Patients with TAG-72 Positive Ovarian and Prostate Cancer

CC -4047 -MM-003 : A phase 3, multicenter , randomized, open – label study to compare the efficacy and safety of pomalidomide in combination with low-dose dexamethasone versus high-dose dexamethasone in subjects with refractory or relapsed and refractory multiple myeloma

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician’s Choice in Subjects with Advanced Non-Small Cell Lung Cancer.

AZ OIC :A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Relieving Opioid-Induced Constipation (OIC) in Patients with Cancer-Related Pain

BR26: A double blind placebo controlled randomised trial of PF-00299804 (PF-804) in patients with incurable stage IIIB/IV non-small cell lung cancer after failure of standard therapy for advanced or metastatic disease.

ROMANA 2- Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC-C

ROMANA 3 - Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): An Extension Study

ATTAX-3: A randomised phase II study evaluating weekly docetaxel, cisplatin, fluoropyrimidine (wTCF) plus or minus panitumumab in advanced oesophago-gastric cancer.

CA184-104 : Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC).

A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus CVP vs. MabThera® plus CVP, Followed by GP2013 or MabThera® Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma

BO21223 : A multicenter, Phase III, Open-Label, randomized study in previously untreated patients with advanced indolent Non-Hodgkin’s Lymphoma evaluating the benefit of GA101 (RO5072759) plus chemotherapy compared with rituximab plus chemotherapy followed by GA101 or rituximab maintenance therapy in responders

A PHASE-3, MULTI-CENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE EFFICACY AND SAFETY OF POMALIDOMIDE IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM -ASSOCIATED MYELOFIBROSIS AND RED BLOOD CELL-TRANSFUSION DEPENDENCE

A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Advanced Solid Tumors

An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of vemurafenib in metastatic melanoma patients with brain metastases

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects with Advanced Solid Tumor Types Likely to Express Epidermal Growth Factor Receptor (EGFR)

An Extension Study of ABT-806 for Subjects with Advanced Solid Tumors

A Phase II, Open-Label Extension Study Evaluating the Long Term Safety, Tolerability & Efficacy of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis.

A Phase I/II trial to determine the Safety, Toxicity and Efficacy of Iodine-131-Rituximab and the Histone Deacetylase Inhibitor Panobinostat in Relapsed and Refractory Indolent B-cell Lymphoma

ADMYRE: Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma.

A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma
Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)

Protocol Number : 20090505

VALOR: A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia

BRIM: A Phase II trial of bortezomib and dexamethasone in
renally-impaired patients with untreated multiple myeloma

A phase Ib, open-label, multi-center, dose escalation and expansion study of an orally administered combination of BEZ235 plus MEK162 in adult patients with selected advanced solid tumors.

A randomised double-blind multi-site parallel arm controlled trial to assess relief of refractory breathlessness comparing fixed doses of morphine, oxycodone and placebo.

Otsuka Pancreatic : Phase 2 Active-controlled Double-Blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-Advanced Pancreatic Cancer

MDS4 - A Randomised Phase II study comparing the efficacy of 5azacitidine alone versus combination therapy with lenalidomide and 5azacitidine in patients with higher risk myelodysplastic syndromes (MDS) and low marrow blast count acute myeloid leukaemia (AML).

Paragon : Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms

A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

A randomized, double-blind, placebo-controlled, multicenter, Phase III study of TKI258 plus Best Supportive Care (BSC) versus placebo plus BSC in patients with metastatic renal cell carcinoma who have progressed following VEGF targeted and mTOR inhibitor therapy

PROSELICA - Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen

ENESTxtnd: Extending molecular responses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase

Circulating Tumour DNA as a Sensitive and Specific Marker of Response to Therapy and of Occult Disease in Colorectal Cancer

CML10 : Response post Tyrosine Kinase Inhibitor: assessment of sensitivity and therapeutic response to next-line therapy in CML: The Australasian RESIST study

A phase II, multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation

FIRSTANA: Randomized, Open Label, Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer not Pretreated with Chemotherapy

TRINOVA-2 - A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

002/07 : Randomised control trial of oral risperidone, oral haloperidol, and oral placebo with rescue subcutaneous midazolam in the management of delirium in palliative care inpatients.

An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma

PROFILE 1014 - Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus

PICASSO - A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic soft tissue sarcoma

Leopard - A PHASE II STUDY OF LENALIDOMIDE AND PREDNISOLONE AS POST-ASCT MAINTENANCE THERAPY FOR PATIENTS WITH MULTIPLE MYELOMA INCORPORATING RESIDUAL DISEASE MONITORING

CLL6 (RESIDIUM) - An Australasian, Phase III, Multicentre, Randomised Trial Comparing Lenalidomide Consolidation Vs No Consolidation in Patients With Chronic Lymphocytic Leukemia and Residual Disease Following Induction Chemotherapy

An Open-Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy

Randomised control trial of oral risperidone, oral haloperidol, and oral placebo with rescue subcutaneous midazolam in the management of delirium in palliative care inpatients.

Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-906024 in Subjects with Advanced Solid Tumors

BRIM7: A Phase Ib, Open label, Dose-Escalation Study evaluating the Safety, Tolerability and Pharmacokinetics of RO5185426 in Combination with GDC-0973 when Administered in Patients with BRAFV600E Positive Metastatic Melanoma who have Progressed after treatment with RO5185426

GAMMA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas

A phase II, single-arm study of orally administered BKM120 as second-line therapy in patients with advanced endometrial carcinoma

A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects with Myelofibrosis

A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia

CABARET: A randomised phase II study of Carboplatin and Bevacizumab in Recurrent Glioblastoma Multiforme

OUTBACK: A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally-advanced cervical cancer compared to chemoradiation alone

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Docetaxel-based Therapy

A multicentre, randomized, double-blind, placebo-controlled, parallel-design trial of the efficacy and safety of subcutaneous tetrodotoxin (Tectin™) for moderate to severe inadequately controlled cancer-related pain

A MULTICENTRE, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY CONTINUATION STUDY OF SUBCUTANEOUS TETRODOTOXIN (TECTIN™) FOR MODERATE TO SEVERE CANCER-RELATED PAIN

RAINBOW: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel with or without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine

PACT NSCLC ALTG questionnaire :Preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile to patients and their doctors?

TRINOVA - 1 - A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

RESPONSE: Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care

FRANC: A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

A single arm pilot study of 5-azacitidine in myelodysplastic syndrome / acute myeloid leukaemia, with eltrombopag support for thrombocytopenia

A Phase 3, Multicenter, Randomized, Open-label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia

PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination with Paclitaxel and Carboplatin in Subjects with High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Malignancies

A Randomized, Open-Label, Phase 2 Study of CNTO 328 (Anti-IL6 Monoclonal Antibody) and Velcade-Melphalan-Prednisone Compared with Velcade-Melphalan-Prednisone for the treatment of Previously Untreated Multiple Myeloma.

A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects with Any Hematologic Malignancy

MARIANNE: A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2- positive progressive or recurrent locally advanced or metastatic breast cancer (MBC)

SQUIRE: A Randomized, Multicenter, Open-Label, Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients with Advanced Cancer

SORBET: A single arm prospective phase II study of tamoxifen in triple negative (oestrogen receptor alpha negative, HER-2 negative) but oestrogen receptor beta positive metastatic breast cancer

Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer

The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A randomized, phase III, open label, multi-center, two-arm study to compare the efficacy of Tasigna® versus dacarbazine (DTIC) in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation

EVOLVE-1: A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after failure of sorafenib treatment

PROLONG: A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy

A Phase 1, Open-label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-MET/ALK Inhibitor (PF-02341066) and PAN-HER Inhibitor (PF-00299804) in Patients with Advanced Non-Small Cell Lung Cancer.

A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy

An Open-label, Multiple Ascending Dose (MAD) Study of the Selective BRAF Inhibitor RO5212054 (PLX3603) to Evaluate Safety, Tolerability and Pharmacokinetics in Patients with V600-mutated Advanced Solid Tumours

D-CARE: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence

CATNON: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma.

AYA PK: Pharmacokinetics and Pharmacodynamics of Doxorubicin in Children, Adolescents and young adults with Newly Diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma A Multi-Institutional Cross-Discipline Non-Therapeutic Study

LAP07: Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib

A Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared with Best Supportive Care in Subjects with Multicentric Castleman's Disease

ORIGIN: A Phase 3, Multicenter, Randomized, Open-label, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-line Therapy for Elderly Patients with B-Cell Chronic Lymphocytic Leukemia

PROArCT - A PHASE II TRIAL OF INTEGRATED PREOPERATIVE RADIOTHERAPY AND CHEMOTHERAPY WITH OXALIPLATIN 5-FU AND FOLINIC ACID IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER

A Phase 1 Multiple Ascending Dose Study of BMS-754807 in Combination with Paclitaxel and Carboplatin in Subjects with Advanced or Metastatic Solid Tumors

MAINSAIL: A Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in subjects with castrate-resistant prostate cancer

SPARK-AML1: A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in patients aged > or equal to 60 with newly diagnosed acute myeloid leukaemia (AML) who are considered unsuitable to receive intensive induction chemotherapy regimens.

PAVES: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab and Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)

Phase 3, Randomized, Open-Label Study of The Efficacy and Safety of PF-02341066 Versus Standard of Care Chemotherapy (Pemetrexed or Docetaxel) in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) Harboring A Translocation or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus

Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of Pf-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus

ASPECCT: A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer

Sympton Benefit: Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer? Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer

BOLERO-1: A randomized phase III, double-blind, placebo-controlled multicenter trial of Everolimus in combination with Trastuzumab and Paclitaxel, as first line therapy in women with HER2 positive locally advanced or metastatic breast cancer

NHL21: Early treatment intensification with R-ICE chemotherapy followed by autologous stem cell transplantation using Z-BEAM for patients with poor prognosis diffuse large B-cell lymphoma as identified by interim PET-/CT scan performed after four cycles of R-CHOP-14 chemotherapy

A Single Arm, Phase II study of the anti-Blys monoclonal antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia

EnGeneIC: A Phase 1 Study of Epidermal Growth Factor Receptor (EGFR) Targeted, Paclitaxel Loaded EnGeneIC Delivery Vehicles (Erbitux(R)EDVsPac) in Patients with Advanced Epithelial Malignancies

M07-001: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

An Open-Label, Multi-center, Phase 2 Study of the Denosumab in Subjects with Giant cell Tumour of Bone.

Phase 1 Clinical Trial of NPI-0052 in Patients with Advanced Malignancies.

A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme(R)) Enzyme Replacement Therapy

A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas.

Phase 1 safety, pharmacokinetic and pharmacodynamic study of PF-02341066, a c-met/hgfr selective tyrosine kinase inhibitor, administered orally to patients with advanced cancer.

Phase I Multiple Ascending Dose Study of BMS-754807 in Subjects with Advanced or Metastatic Solid Tumors.